Qiagen (NYSE:QGEN) Issues FY 2026 Earnings Guidance

Qiagen (NYSE:QGEN) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 2.500- for the period, compared to the consensus earnings per share estimate of 2.630. The company issued revenue guidance of $2.2 billion-, compared to the consensus revenue estimate of $2.2 billion. Qiagen also updated its Q1 2026 guidance to 0.540- EPS.

Qiagen Stock Performance

NYSE:QGEN traded down $0.10 on Wednesday, reaching $51.79. 2,381,654 shares of the company’s stock were exchanged, compared to its average volume of 3,079,245. The firm has a market cap of $10.94 billion, a price-to-earnings ratio of 26.74, a P/E/G ratio of 2.49 and a beta of 0.67. The stock has a fifty day simple moving average of $49.60 and a 200-day simple moving average of $49.64. Qiagen has a 52 week low of $39.61 and a 52 week high of $57.81. The company has a debt-to-equity ratio of 0.45, a current ratio of 2.60 and a quick ratio of 2.30.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.03. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. As a group, sell-side analysts predict that Qiagen will post 2.26 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on QGEN. Deutsche Bank Aktiengesellschaft cut Qiagen from a “buy” rating to a “hold” rating and lifted their price objective for the company from $52.00 to $54.00 in a research report on Thursday, January 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Wall Street Zen lowered shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. UBS Group reissued a “neutral” rating on shares of Qiagen in a research report on Wednesday, January 21st. Finally, Citigroup cut Qiagen from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $57.89 to $52.63 in a research report on Thursday, December 11th. Two research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat, Qiagen presently has a consensus rating of “Hold” and a consensus price target of $53.04.

Institutional Investors Weigh In On Qiagen

Institutional investors have recently added to or reduced their stakes in the stock. Danske Bank A S bought a new stake in Qiagen during the 3rd quarter worth approximately $36,000. Advisory Services Network LLC bought a new stake in Qiagen during the third quarter valued at about $64,000. EverSource Wealth Advisors LLC raised its position in Qiagen by 226.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company’s stock valued at $125,000 after purchasing an additional 1,802 shares during the period. Osaic Holdings Inc. grew its stake in Qiagen by 101.4% in the second quarter. Osaic Holdings Inc. now owns 3,875 shares of the company’s stock worth $185,000 after purchasing an additional 1,951 shares in the last quarter. Finally, Pitcairn Co. acquired a new position in Qiagen during the 2nd quarter valued at about $208,000. 70.00% of the stock is owned by institutional investors.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.